

treat analysis), but it was significantly lower when only those with adequate recordings were included.

Under the FDA's requirement for training, clinicians must be certified based on a written test and credentialed based on an oral exam that is administered after successful completion of at least five "practice cases," according to Dr. Carey-Corrado.

Physician certification is something the FDA's advisory panel called for in June, and the FDA deliberately structured its training requirement to resemble the training that was required of clinicians in the U.S. bridging studies, she said.

Dr. Hankins questioned how such a re-

quirement could be enforced and said that training is ultimately "under local purview." When asked about enforcement, the FDA's Mr. Pollard acknowledged the validity of the question and said that the agency's authority "does not extend beyond the labeling."

The STAN S31 system is indicated for use in patients with planned vaginal delivery, greater than 36 weeks of gestation, a singleton fetus, vertex presentation, and ruptured amniotic membranes. Simon Grant, CEO of Neoventa, the monitor's Swedish manufacturer, said the company intends to partner with a U.S. company to introduce the device to the U.S. market this year. ■



The upper trace of this STAN S31 recording is the fetal heart rate, the bottom shows uterine contractions. The black flag above marks an ST-segment event.


Brought to you by **sanofi aventis**

**THE ECS IMPACTS THE METABOLISM OF LIPIDS AND GLUCOSE<sup>1-3</sup>**

- ECS overactivity may be associated with the development of cardiometabolic risk factors including:
  - Low HDL cholesterol
  - High triglycerides
  - High waist circumference
  - Elevated fasting glucose
  - Insulin resistance

**THE ECS HELPS REGULATE PHYSIOLOGIC PROCESSES<sup>1-4</sup>**

- The ECS consists of signaling molecules and their receptors, including the cannabinoid receptor CB<sub>1</sub><sup>2</sup>
- Endocannabinoids bind to CB<sub>1</sub> receptors and trigger events that may have a negative impact on lipid levels and insulin sensitivity<sup>1</sup>
- CB<sub>1</sub> receptors are located in sites such as muscle, the liver, the brain, and adipose tissue<sup>1,2,4,6</sup>



**RESEARCH CONTINUES TO INVESTIGATE THE ROLE OF CB<sub>1</sub> RECEPTORS IN MUSCLE\***

- Reduced glucose uptake has been observed in isolated skeletal muscle of genetically obese, insulin-resistant animals



**ENDOCANNABINOID TARGET FATTY ACID PRODUCTION IN THE LIVER<sup>3</sup>**

- May contribute to dyslipidemia and insulin resistance<sup>3,7</sup>



**PRESENT IN MULTIPLE AREAS OF THE BRAIN<sup>2</sup>**

- Hypothalamus integrates signals from adipose tissue and other peripheral tissues<sup>8,9</sup>



**ADIPOSE TISSUE—MORE THAN SIMPLY A FAT STORAGE DEPOT**

- Produces factors active in the metabolism of lipids and glucose<sup>10</sup>
- Low levels of adiponectin negatively affect glucose and free fatty acids<sup>1,10</sup>

**EXPLORING THE EFFECTS OF THE ECS**

- This newly discovered physiologic system provides new opportunities for understanding cardiometabolic risk

\*Data from animal model only.

**References**

1. Bensaid M, Gary-Bobo M, Esclançon A, et al. The cannabinoid CB<sub>1</sub> receptor antagonist SR141716 increases Acip30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. *Mol Pharmacol*. 2003;63:908-914. 2. Harrold JA, Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating? *Br J Nutr*. 2003;90:729-734. 3. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB<sub>1</sub> receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J Clin Invest*. 2005;115:1298-1305. 4. Domenicali M, Ros J, Fernández-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. *Gut*. 2005;54:522-527. 5. Rhee M-H, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. *J Neurochem*. 1998;71:1525-1534. 6. Upham BL, Rummel AM, Carbone JM, et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. *Int J Cancer*. 2003;104:12-18. 7. Flier JS, Maratos-Flier E. Obesity. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. *Harrison's Principles of Internal Medicine*. 16th ed. New York, NY: McGraw-Hill; 2005:chap 64. Available at: <http://www.accessmedicine.com/content.aspx?alD=60099&searchStr=obesity>. Accessed December 5, 2005. 8. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. *Science*. 2005;307:1909-1914. 9. Devaskar SU. Neurohumoral regulation of body weight gain. *Pediatr Diabetes*. 2001;2:131-144. 10. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004;89:2548-2556.

## GERD Overlooked, Undertreated in Pregnant Women

SCOTTSDALE, ARIZ. — Gastroesophageal reflux disease may be underreported and undertreated in pregnant women, according to a poster presented at the annual meeting of the Central Association of Obstetricians and Gynecologists.

Dr. Houmam Al-Hakeem and his coinvestigators at Southern Illinois University in Springfield diagnosed the condition in 72 of 111 pregnant women screened with the Gastrointestinal Symptom Rating Scale Questionnaire, a measure validated in published studies.

The poster reported that a 2-week trial of conservative management, described as "the first line of treatment in pregnant women," failed to improve the cumulative scores of the women who had symptoms of gastroesophageal reflux disease (GERD).

GERD "is very common in pregnancy but at the same time it is very overlooked," Dr. Al-Hakeem said in an interview.

Conservative management, as prescribed in the study, includes not lying down after meals, avoiding certain foods, raising the head of the bed, and taking antacids. Physicians know this does not work, and prescribe drugs as a first-line treatment in GERD patients who are not pregnant, according to Dr. Al-Hakeem, who now practices in San Antonio.

"Why are we waiting during pregnancy?" he asked. "Because we are afraid to give medicine."

He said the investigators have begun the second phase of the study: a double-blind crossover trial of GERD treatments in a pregnant population. The study will look at fetal outcomes and reflux symptoms in patients treated with conservative management, the drugs Zantac and Prevacid, and a placebo. Dr. Al-Hakeem anticipated results would be available in about a year.

The 111 patients in the first phase were in good health in a pregnancy of at least 24 weeks' gestation. Patients with documented history of GERD, esophageal disorders, Zollinger-Ellison syndrome, hiatal hernia, peptic ulcer syndrome, and irritable bowel syndrome were excluded.

The investigators found no significant differences in ethnicity, education, tobacco use, or alcohol and drug use between the 72 women deemed to be GERD positive and the 39 women who were not.

—Jane Salodof MacNeil